SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY” or the “Company”) UBXa biotechnology company developing therapeutics to slow, halt or reverse the diseases of aging, announced today that on Tuesday, 1 am ET, it met with retinal expert and key opinion leader Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research at Sierra Eye Associates.
The live webcast is available in the “Investors and Media” section of our website, www.unitybiotechnology.comunder “Events & Presentations” or by clicking here. A replay will be available two hours after the call closes and can be accessed in the Investors & Media section of our website under Events and Presentations.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse the diseases of aging. UNITY’s current focus is on developing drugs to selectively eliminate or modulate senescent cells and thereby deliver transformative benefits in age-related ophthalmic and neurological diseases. For more information, see www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
investor contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
media contact
Invoke Canale
Catherine Smith
Katherine.Smith@evokegroup.com
